A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning

Trial Profile

A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2015

At a glance

  • Drugs T-cell vaccine-AlloStim (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Immunovative Therapies
  • Most Recent Events

    • 02 Apr 2015 Status changed from suspended to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 24 Nov 2014 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 24 Nov 2014 Status changed from discontinued to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top